復宏漢霖(02696.HK):HLX04-O用於wAMD治療1期臨牀研究在內地完成首例患者給藥
格隆匯7月19日丨復宏漢霖(02696.HK)發佈公吿,近日,用於濕性年齡相關性黃斑變性(wAMD)治療的重組抗VEGF人源化單克隆抗體注射液HLX04-O(“HLX04-O”)的1期臨牀研究於中國大陸(不包括港澳台地區,下同)完成首例患者給藥。
根據披露,本次研究是一項在濕性年齡相關性黃斑變性(wAMD)患者中開展的單臂1期臨牀研究。作為安全導入期,本研究計劃入組6-12名患者,主要目的為評價HLX04-O在wAMD患者研究眼中的安全性和耐受性,次要目的為評估 HLX04-O玻璃體注射給藥後的全身藥代動力學特徵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.